Keudell Morrison Wealth Management bought a new stake in Astrazeneca Plc (NYSE:AZN – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 4,789 shares of the company’s stock, valued at approximately $840,000.
Other large investors have also recently made changes to their positions in the company. Cibc World Market Inc. boosted its position in shares of Astrazeneca by 21.5% in the 3rd quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock valued at $4,942,000 after purchasing an additional 11,398 shares during the period. TD Asset Management Inc boosted its position in shares of Astrazeneca by 20.0% in the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock valued at $83,595,000 after purchasing an additional 181,273 shares during the period. AMG National Trust Bank boosted its position in shares of Astrazeneca by 20.4% in the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock valued at $3,298,000 after purchasing an additional 7,289 shares during the period. Y Intercept Hong Kong Ltd boosted its position in shares of Astrazeneca by 111.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company’s stock valued at $5,113,000 after purchasing an additional 35,148 shares during the period. Finally, Oxbow Advisors LLC boosted its position in shares of Astrazeneca by 96.2% in the 3rd quarter. Oxbow Advisors LLC now owns 77,594 shares of the company’s stock valued at $5,953,000 after purchasing an additional 38,043 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.
Astrazeneca Stock Up 1.3%
Astrazeneca stock opened at $189.88 on Friday. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The stock has a 50 day moving average of $191.76 and a two-hundred day moving average of $182.72. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $294.49 billion, a price-to-earnings ratio of 28.51, a PEG ratio of 1.54 and a beta of 0.26.
Analyst Ratings Changes
AZN has been the subject of a number of research analyst reports. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Barclays raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings assumed coverage on Astrazeneca in a research report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $205.33.
Read Our Latest Stock Analysis on Astrazeneca
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Stories
- Five stocks we like better than Astrazeneca
- Intuit’s Great SaaS Reset: Fired By AI
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
